Dermata Therapeutics DRMA Stock
Dermata Therapeutics Price Chart
Dermata Therapeutics DRMA Financial and Trading Overview
| Dermata Therapeutics stock price | 0.93 USD |
| Previous Close | 1.74 USD |
| Open | 1.74 USD |
| Bid | 0 USD x 3200 |
| Ask | 0 USD x 1400 |
| Day's Range | 1.72 - 1.9 USD |
| 52 Week Range | 0.98 - 16.64 USD |
| Volume | 212.06K USD |
| Avg. Volume | 3.18M USD |
| Market Cap | 5.27M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -8.03 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 90 USD |
DRMA Valuation Measures
| Enterprise Value | -4698366 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.6607143 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.54620606 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Dermata Therapeutics Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | -76.11% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 16.64 USD |
| 52 Week Low | 0.98 USD |
| 50-Day Moving Average | 1.85 USD |
| 200-Day Moving Average | 5.44 USD |
DRMA Share Statistics
| Avg. Volume (3 month) | 3.18M USD |
| Avg. Daily Volume (10-Days) | 313.61K USD |
| Shares Outstanding | 2.85M |
| Float | 2.07M |
| Short Ratio | 0.01 |
| % Held by Insiders | 28.93% |
| % Held by Institutions | 1.01% |
| Shares Short | 21.88K |
| Short % of Float | 0.85% |
| Short % of Shares Outstanding | 0.77% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:16 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -62.47% |
| Return on Equity (ttm) | -113.73% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -9064903 USD |
| Diluted EPS (ttm) | -10.54 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 8.77M USD |
| Total Cash Per Share (mrq) | 3.75 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 7.701 |
| Book Value Per Share (mrq) | 3.387 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -7875949 USD |
| Levered Free Cash Flow (ttm) | -4539805 USD |
Profile of Dermata Therapeutics
| Country | United States |
| State | CA |
| City | San Diego |
| Address | 3525 Del Mar Heights Road |
| ZIP | 92130 |
| Phone | 858 800 2543 |
| Website | https://www.dermatarx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 8 |
Dermata Therapeutics, Inc., a clinical-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Q&A For Dermata Therapeutics Stock
What is a current DRMA stock price?
Dermata Therapeutics DRMA stock price today per share is 0.93 USD.
How to purchase Dermata Therapeutics stock?
You can buy DRMA shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Dermata Therapeutics?
The stock symbol or ticker of Dermata Therapeutics is DRMA.
Which industry does the Dermata Therapeutics company belong to?
The Dermata Therapeutics industry is Biotechnology.
How many shares does Dermata Therapeutics have in circulation?
The max supply of Dermata Therapeutics shares is 5.43M.
What is Dermata Therapeutics Price to Earnings Ratio (PE Ratio)?
Dermata Therapeutics PE Ratio is now.
What was Dermata Therapeutics earnings per share over the trailing 12 months (TTM)?
Dermata Therapeutics EPS is -8.03 USD over the trailing 12 months.
Which sector does the Dermata Therapeutics company belong to?
The Dermata Therapeutics sector is Healthcare.
Dermata Therapeutics DRMA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16550.61 USD — |
-5.97
|
8.29B USD — | 16533.04 USD — | 16889.34 USD — | — - | 8.29B USD — |
| NASDAQ HealthCare IXHC | 920.53 USD — |
-2.33
|
— — | 917.85 USD — | 930.28 USD — | — - | — — |
- {{ link.label }} {{link}}